Immunopharmacology: Immunomodulation and Immunotherapy

JAMA: The Journal of the American Medical Association

Volumn 268, Issue 20, 1992, Pages 2964-2969

  Hadden, John W ^a   Smith, David L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOSPORIN; CYTOKINE; CYTOTOXIC AGENT; FOLIC ACID ANTAGONIST; GLUCOCORTICOID; INTERFERON; LEVAMISOLE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THYMUS HORMONE;

APHERESIS; CORTICOSTEROID THERAPY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IONIZING RADIATION; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CYTOKINES; HUMAN; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY;

EID: 0026457524     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03490200216028     Document Type: Article

References (30)

1. Handschumacher RE. Drugs used for immunosuppression. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. The Pharmacologic Basis of Therapeutics. Elmsford, NY: Pergamon Press Inc; 1990: 1264-1276.
2. Stratta RJ, D’Allesandro AM, Hoffman RM, et al. Cadaveric renal transplantation in the cyclosporine and OKT3 eras. Surgery. 1988;104:606-615.
3. Mihich E, Ehrke MJ. Immunomodulation by anticancer compounds. In: Chedid L, Hadden JW, Spreafico F, Dukor P, Willoughby D, eds. Advances in Immunopharmacology III. Elmsford, NY: Pergamon Press Inc; 1986:257-265.
4. Winkelstein A. Immunopharmacology. In: Smith CM, Reynard AM, eds. Textbook of Pharmacology. Philadelphia, Pa: WB Saunders Co; 1992:964-983.
5. Brostoff J, Scadding GK, Male DM, Roitt IM. Clinical Immunology. New York, NY: Gower Medical Publishing; 1991:27.1-28.10.
6. Claman HN. Glucocorticosteroids, I: anti-inflammatory mechanisms. Hosp Prac. 1983;18:123-134.
7. Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983; 2:995-997.
8. Katz P, Fauci AS. Immunosuppressives and immunoadjuvants. In: Samter M, ed. Immunological Diseases. Boston, Mass: Little Brown & Co Inc; 1988:675-698.
9. Johnson WJ, Dimartino MJ, Melnier PC, Muirhead KA, Hanna N. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol. 1988;15:745-749.
10. Keim D, Ragsdale C, Hidelberger K, Sullivan D. Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis. J Rheumatol. 1990; 17:846-848.
11. Borel JF. Cyclosporin A: pharmacological properties in vivo. Pharmacol Rev. 1989;41:259-371.
12. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol. 1992; 10:519-560.
13. Schaller JG. Kawasaki disease. In: Behrman RE, ed. Nelson Textbook of Pediatrics. Philadelphia, Pa: WB Saunders Co; 1992:629-631.
14. Corrigan JJ. Idiopathic thrombocytopenic purpura. In: Behrman RE, ed. Nelson Textbook of Pediatrics. Philadelphia, Pa: WB Saunders Co; 1992: 1281-1282.
15. Friedman H, Specter S, Klein T. Drugs of Abuse, Immunity and Immunopharmacology. New York, NY: Plenum Press; 1991.
16. Descotes J. Immunotoxicology of Drugs and Chemicals. Amsterdam, the Netherlands: Elsevier Science Publishers; 1986.
17. Bizzini B, Bonmassar E. Advances in Immunomodulation. Rome, Italy: Pythagora Press; 1988.
18. Hadden JW, Hadden EM. Therapy of secondary T cell immunodeficiencies with biological substances and drugs. Med Oncol Tumor Pharmacother. 1989;12:107-111.
19. Hadden JW. Immunotherapy of human immunodeficiency virus. Trends Pharmacol Sci. 1990; 12:107-111.
20. Taylor CW, Hersh EM. Immunotherapy and biological therapy of cancer: current clinical status and future prospects. In: Hadden JW, Szentivanyi A, eds. Immunopharmacology Reviews. New York, NY: Plenum Press; 1990:89-136.
21. Masihi KN, Lange W. Immunotherapeutic Prospects of Infectious Diseases. Berlin, Germany: Springer-Verlag; 1990.
22. Cruse JM, Lewis RE. Therapy of Autoimmune Diseases. Basel, Switzerland: Karger; 1989.
23. Hadden JW, Renoux G, Chirigos M. The characterization of immunotherapeutic agents. In: Hadden JW, Szentivanyi A, eds. Immunopharmacology Reviews. New York, NY: Plenum Press; 1990: 1-64.
24. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family. Ann Rev Immunol. 1991;9:617-648.
25. Sundal E, ed. Thymopentin in experimental and clinical medicine. Surv Immunol Res. 1985;1(suppl 4):1-156.
26. Kirkpatrick CH. Biological response modifiers: interferons, interleukins, and transfer factor. Ann Allergy. 1989;62:170-176.
27. Renoux G. The general immunopharmacology of levamisole. Drugs. 1980;19:89-99.
28. Tsang KY, Fudenberg HH, Hoehler FK, Hadden JW. Immunostimulating compounds: isoprinosine and NPT 15396. In: Fenichel RL, Chirigos MA, eds. Immune Modulation Agents and Their Mechanisms. New York, NY: Marcel Dekker Inc; 1984:79-95.
29. Lederer E. Natural and synthetic immunomodulators derived from the mycobacterial cell wall. In: Bizzini B, Bonmassar E, eds. Advances in Immunomodulation. Rome, Italy: Pythagora Press; 1988: 9-36.
30. White WB, Ballow M. Modulation of suppressorcell activity in cimetidine in patients with common variable hypogammaglobulinemia. N Engl J Med. 1985;312:198-202.